Hubert S.
- Country
- Germany
- Department
- Institut für Transfusionsmedizin
Research Overview
- A multicenter, single arm, open-label trial to evaluate efficacy and safety of oral, twice daily iptacopan in adult PNH patients who have Hb≥10 g/dL in response to anti-C5 antibody and switch to iptacopan
- Efficacy and Safety Evaluation of Crovalimab Versus Eculizumab in Complement Inhibitor-Naïve Patients with Paroxysmal Nocturnal Hemoglobinuria
- Evaluation of Long-Term Safety and Tolerability of Iptacopan in Patients with Paroxysmal Nocturnal Hemoglobinuria Post-Phase II/III Studies
Data & Insights
Has run more than one trial at 17 of 53 partner sites.
Specializations
Rare Blood Disorders
Specialized in treating Paroxysmal Nocturnal Hemoglobinuria (PNH), a rare acquired blood disorder affecting red blood cells.
- Novel complement inhibitor therapies
- Treatment-naïve patient care
- Long-term disease management
Focuses on evaluating innovative therapeutic approaches for patients with varying response levels to standard treatments.
Therapeutic Innovation
Investigates multiple complement pathway inhibitors including crovalimab, iptacopan, and OMS906 for blood disorders.
- Alternative treatment pathways
- Oral therapeutic options
- Treatment switching strategies
Explores both intravenous and oral administration routes to optimize patient treatment outcomes.
Clinical Assessment
Conducts comprehensive evaluation of treatment efficacy and safety profiles in hematological conditions.
- Long-term safety monitoring
- Treatment tolerability assessment
- Pharmacodynamic evaluation
Specializes in monitoring therapeutic responses and maintaining long-term patient follow-up.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.